Payment overview · 2025
General Payments
$384.60
16 reported records · 7 companies
Healthcare provider profile · identity verified
Jonathan Edward Eckstein, DO
Allopathic & Osteopathic Physicians|Family Medicine · HOWARD BEACH, NY · NPI 1346266699
Verified facts
What the public records show
CMS Open Payments records show Jonathan Edward Eckstein, DO received $384.60 in general payments during 2025 across 16 reported records.
AstraZeneca Pharmaceuticals LP accounted for 36.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Mounjaro, Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Farxiga by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Eliquis by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $141.27 | 36.7% | 6 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $93.36 | 24.3% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $44.36 | 11.5% | 2 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $35.59 | 9.2% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $31.06 | 8.1% | 1 | 2025 |
| Galderma Laboratories, L.P. | Unresolved — no canonical attribution shown | $23.90 | 6.2% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $15.06 | 3.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $384.60 | 16 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $79.87 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $61.40 | 3 | 2025 |
Source payment records
|
|||||
| Saxenda Normalized: saxenda |
Drug | Novo Nordisk Inc | $42.10 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $42.10 | 2 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $35.59 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $31.06 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $25.37 | 1 | 2025 |
Source payment records
|
|||||
| NEMLUVIO Normalized: nemluvio |
Drug | Galderma Laboratories, L.P. | $23.90 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $17.43 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $17.43 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $15.06 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
56 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
45 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 383 | 109 |
| Amlodipine Besylate | Amlodipine Besylate | 382 | 119 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 271 | 90 |
| Levothyroxine Sodium | Levothyroxine Sodium | 235 | 61 |
| Metoprolol Succinate | Metoprolol Succinate | 235 | 68 |
| Losartan Potassium | Losartan Potassium | 190 | 59 |
| Gabapentin | Gabapentin | 184 | 59 |
| Metformin Hcl Er | Metformin Hcl | 166 | 54 |
| Metformin Hcl | Metformin Hcl | 156 | 52 |
| Omeprazole | Omeprazole | 135 | 40 |
| Famotidine | Famotidine | 132 | 44 |
| Lisinopril | Lisinopril | 102 | 30 |
| Simvastatin | Simvastatin | 101 | 33 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 99 | 29 |
| Montelukast Sodium | Montelukast Sodium | 98 | 35 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 83 | 19 |
| Pioglitazone Hcl | Pioglitazone Hcl | 83 | 24 |
| Tamsulosin Hcl | Tamsulosin Hcl | 72 | 27 |
| Trazodone Hcl | Trazodone Hcl | 70 | 19 |
| Hydrochlorothiazide | Hydrochlorothiazide | 68 | 23 |
| Jardiance | Empagliflozin | 56 | 16 |
| Methylprednisolone | Methylprednisolone | 55 | 48 |
| Escitalopram Oxalate | Escitalopram Oxalate | 49 | 16 |
| Atenolol | Atenolol | 48 | 11 |
| Azithromycin | Azithromycin | 46 | 39 |
| Clopidogrel | Clopidogrel Bisulfate | 46 | 11 |
| Mirtazapine | Mirtazapine | 45 | 12 |
| Rybelsus | Semaglutide | 45 | 12 |
| Verapamil Er | Verapamil Hcl | 44 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 42 | 20 |
| Pantoprazole Sodium | Pantoprazole Sodium | 42 | 17 |
| Azelastine Hcl | Azelastine Hcl | 41 | 23 |
| Ezetimibe | Ezetimibe | 41 | suppressed |
| Valsartan | Valsartan | 40 | 12 |
| Enalapril Maleate | Enalapril Maleate | 39 | suppressed |
| Alprazolam | Alprazolam | 36 | 16 |
| Irbesartan | Irbesartan | 33 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 33 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 33 | suppressed |
| Cefdinir | Cefdinir | 32 | 29 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 32 | suppressed |
| Folic Acid | Folic Acid | 31 | suppressed |
| Furosemide | Furosemide | 30 | 12 |
| Mounjaro | Tirzepatide | 30 | suppressed |
| Synthroid | Levothyroxine Sodium | 30 | suppressed |
| Ozempic | Semaglutide | 29 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 29 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 29 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 28 | suppressed |
| Glipizide Er | Glipizide | 27 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 26 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 26 | 22 |
| Zolpidem Tartrate | Zolpidem Tartrate | 26 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 25 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 25 | suppressed |
| Spironolactone | Spironolactone | 24 | suppressed |
| Fenofibrate | Fenofibrate | 23 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 22 | suppressed |
| Finasteride | Finasteride | 22 | suppressed |
| Colchicine | Colchicine | 21 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 21 | suppressed |
| Eliquis | Apixaban | 21 | suppressed |
| Ibuprofen | Ibuprofen | 21 | suppressed |
| Meloxicam | Meloxicam | 21 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 21 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 20 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 20 | 14 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 19 | suppressed |
| Januvia | Sitagliptin Phosphate | 19 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 19 | suppressed |
| Allopurinol | Allopurinol | 18 | suppressed |
| Clonazepam | Clonazepam | 18 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 18 | suppressed |
| Naproxen | Naproxen | 17 | suppressed |
| Olopatadine Hcl | Olopatadine Hcl | 17 | suppressed |
| Ramipril | Ramipril | 17 | suppressed |
| Xarelto | Rivaroxaban | 17 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 16 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 16 | suppressed |
| Silodosin | Silodosin | 15 | suppressed |
| Carvedilol | Carvedilol | 14 | suppressed |
| Celecoxib | Celecoxib | 14 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Trulicity | Dulaglutide | 14 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | 12 |
| Fenofibrate | Fenofibrate Nanocrystallized | 13 | suppressed |
| Methadone Hcl | Methadone Hcl | 13 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 13 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Gemfibrozil | Gemfibrozil | 12 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 12 | suppressed |
| Potassium Chloride | Potassium Chloride | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Verapamil Sr | Verapamil Hcl | 12 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $384.60 · 16 records | AstraZeneca Pharmaceuticals LP | ACCRUFER, AIRSUPRA, Dexcom G6 Transmitter, ELIQUIS, FARXIGA, MOUNJARO, NEMLUVIO, Ozempic, Saxenda, Wegovy, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error